Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

[1]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2009, The oncologist.

[2]  P. Adamson,et al.  A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study , 2008, Pediatric blood & cancer.

[3]  J. Blay,et al.  Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors , 2006, Clinical Cancer Research.

[4]  P. Zbinden,et al.  METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS , 2005, Drug Metabolism and Disposition.

[5]  A. Racine‐Poon,et al.  Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. , 2005, British journal of clinical pharmacology.

[6]  J. Verweij,et al.  Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group , 2005, Cancer Chemotherapy and Pharmacology.

[7]  M. Bernstein,et al.  Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. , 2004, Blood.

[8]  M. Egorin,et al.  Biliary Excretion of Imatinib Mesylate and Its Metabolite CGP 74588 in Humans , 2004, Pharmacotherapy.

[9]  B. Dörken,et al.  Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 , 2004, Cancer Chemotherapy and Pharmacology.

[10]  A. Racine‐Poon,et al.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Ben-Am,et al.  Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion , 2004, Journal of clinical pharmacology.

[12]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates , 2004, Clinical Cancer Research.

[13]  R. Capdeville,et al.  Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules , 2004, Cancer Chemotherapy and Pharmacology.

[14]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  F. Tse,et al.  High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  O. S. Nielsen,et al.  Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.

[17]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[18]  P. D. Dal Cin,et al.  Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. , 2001, Cancer research.

[19]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[21]  A. Chott,et al.  Platelet-Derived Growth Factor-AA and -α Receptor Expression Suggests an Autocrine and/or Paracrine Loop in Osteosarcoma , 2000, Modern Pathology.

[22]  G. Kearns,et al.  Cytochrome P450 3A , 1999, Clinical pharmacokinetics.

[23]  S. Wingren,et al.  Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and in vivo. , 1999, Cancer letters.

[24]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[25]  G. Wilkinson.  Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[27]  Imke H. Bartelink,et al.  Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations , 2006, Clinical pharmacokinetics.

[28]  Peter Lloyd,et al.  Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.

[29]  Nicholas H. G. Holford,et al.  The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots , 2005 .

[30]  FDA approves Gleevec for pediatric leukemia. , 2003, FDA consumer.